A large observational study of cardiovascular outcomes associated with atorvastatin or simvastatin therapy in diabetic patients without prior cardiovascular disease.
Analysis of claims data from 46,076 diabetic patients without cardiovascular disease initiating atorvastatin or simvastatin therapy suggested that, after adjusting for demographic and clinical confounders, use of atorvastatin was associated with fewer cardiovascular events versus simvastatin at doses of similar potency (HR 0.88, 95% CI 0.80-0.97, P=0.01).
Foody
Joanne M
JM
Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02130, USA.
Joyce
Amie T
AT
Jeffers
Barrett W
BW
Liu
Larry Z
LZ
Benner
Joshua S
JS
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000069059:Atorvastatin; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000453:epidemiology; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006279:Health Maintenance Organizations / Q000706:statistics & numerical data; D006538:Heptanoic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D011243:Preferred Provider Organizations / Q000706:statistics & numerical data; D011758:Pyrroles / Q000009:adverse effects* / Q000627:therapeutic use; D019821:Simvastatin / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States / Q000453:epidemiology
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D019821:Simvastatin